Allarity Therapeutics, Inc. has announced a significant milestone in its development of stenoparib, a treatment for various cancers. On November 18, 2026, the company revealed that the United States Patent and Trademark Office granted a patent covering specific treatment regimens for stenoparib, which will provide protection until 2045. This patent is crucial for Allarity as it enhances its intellectual property portfolio and supports its ongoing clinical programs.

The granted patent includes 36 claims related to the twice-daily oral administration of stenoparib, detailing specific dosage levels and treatment schedules. This includes methods for treating advanced ovarian cancer and other solid tumors, such as breast and colon cancer. The patent strengthens Allarity’s position in the competitive pharmaceutical preparations industry, particularly as it advances its Phase 2 clinical trials.

Background

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative cancer therapies. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Allarity is publicly traded on the Nasdaq under the ticker symbol ALLR. Recent filings indicate a series of updates regarding the company's progress and operations, including its latest 8-K filing on November 19, 2026.

What the Filing Says

In the recent filing, Allarity stated, "On November 18, 2026, the Company issued a press release announcing that the United States Patent and Trademark Office had granted a U.S. patent covering certain stenoparib treatment regimens." This announcement is a pivotal development for the company as it solidifies its competitive advantage in the market.

Impact

The patent grant is expected to have far-reaching implications for Allarity Therapeutics. It not only secures a legal framework for the company's treatment approaches but also enhances investor confidence and potentially attracts partnerships in the pharmaceutical industry. The patent protection will allow Allarity to focus on its clinical trials without the immediate threat of competition from generic alternatives.

What's Next

The filing does not specify what happens next for Allarity Therapeutics following this patent grant. However, it is likely that the company will continue to advance its clinical trials for stenoparib and explore further opportunities to expand its product offerings in the oncology space.